Menu
Search
|

Menu

Close
X

Athenex Inc ATNX.OQ (NASDAQ Stock Exchange Global Select Market)

12.05 USD
-0.35 (-2.82%)
As of 4:00 PM EDT
chart
Previous Close 12.40
Open 12.47
Volume 114,639
3m Avg Volume 120,793
Today’s High 12.47
Today’s Low 12.00
52 Week High 20.90
52 Week Low 9.87
Shares Outstanding (mil) 67.02
Market Capitalization (mil) 831.09
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
89
FY17
38
FY16
21
EPS (USD)
FY18
-1.801
FY17
-1.930
FY16
-1.512
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
41.05
Price to Sales (TTM)
vs sector
9.33
8.91
Price to Book (MRQ)
vs sector
5.96
4.65
Price to Cash Flow (TTM)
vs sector
--
28.95
Total Debt to Equity (MRQ)
vs sector
33.56
17.48
LT Debt to Equity (MRQ)
vs sector
32.87
13.83
Return on Investment (TTM)
vs sector
-90.46
12.19
Return on Equity (TTM)
vs sector
-102.39
13.29

EXECUTIVE LEADERSHIP

Johnson Lau
Chairman of the Board, Chief Executive Officer, Since 2011
Salary: $200,000.00
Bonus: --
William Zuo
President, Polymed Therapeutic, Since 1995
Salary: --
Bonus: --
Jeffrey Yordon
Chief Operating Officer and President, Athenex Pharmaceutical Division, Since 2017
Salary: $400,000.00
Bonus: $135,000.00
Li Shen
Chief Accounting Officer, Vice President of Financial Reporting, Since 2017
Salary: --
Bonus: --
Rudolf Kwan
Chief Medical Officer, Since 2014
Salary: $288,077.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1001 Main St Ste 600
BUFFALO   NY   14203-1009

Phone: +1716.8988625

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

SPONSORED STORIES